The Harmonic™ trial is a Phase 2 multi-center study focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patient enrollment during Q3 2022. In a previous Phase 3 ...
Please provide your email address to receive an email when new articles are posted on . Muvalaplin, the first oral therapy developed to lower lipoprotein(a), did so in a phase 1 study. An extended ...
PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage ...
SAN DIEGO, March 2, 2025 /PRNewswire/ — Longbio Pharma (Suzhou) Co., Ltd. (referred to as “Longbio”), a leading biotech company dedicated to developing innovative biologic treatments for allergy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results